孟鲁司特联合沙美特罗替卡松气雾剂对慢性阻塞性肺病急性加重期患者肺功能的影响

Effects of Montelukast in Combination With Salmeterol Xinafoateand Fluticasone Propionate Aerosol on Pulmonary Function in Treating Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的探讨孟鲁司特联合沙美特罗替卡松气雾剂对慢性阻塞性肺病急性加重期(AECOPD)患者肺功能的影响。方法 94例符合纳入标准的AECOPD患者随机分为对照(n=47)和观察组(n=47)。常规治疗基础上,对照组给予沙美特罗替卡松气雾剂治疗,观察组在对照组的基础上联合应用孟鲁司特治疗。4周后,观察比较两组临床疗效及肺功能变化情况。结果观察组的治疗总有效率为93.6%,高于对照组78.7%的总有效率,P<0.05,差异具有统计学意义。治疗后,与对照组相比,观察组肺功能指标FEV1和FEV1/FVC显著升高,P<0.05,差异具有统计学意义。结论孟鲁司特联合沙美特罗替卡松气雾剂是AECOPD的有效治疗方案,能够给提高临床疗效,改善肺功能,临床上值得进一步研究。

Objective To explore the effects of montelukast in combination with seretide on pulmonary function in treating acute exacerbation of chronic obstructive pulmonary disease （AECOPD）.Methods94 cases of AECOPD meeting the inclusion criteria were randomly separated into two groups equally. Besides conventional treatments, the control group was treated with seretide, while the observation group was treated with seretide and montelukast. Then, the curative efficacy and pulmonary function were compared.Results The observation group had a therapeutic efficiency ratio of 93.6%, which was significantly higher than that of 78.7% in the control group （P〈0.05）. Comparison with the control group after the treatment, indices of FEV1 and FEV1/FVC relfecting pulmonary function was statistically higher （P〈0.05）.Conclusion Treatment of montelukast in combination with seretide was effective for AECOPD, which could increase curative efifcacy and improve pulmonary function.